Infused Chemotherapy Use in the Elderly After Patent Expiration
Authors:
- 1 May 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 8 (3S) , e18s-e23s
Abstract
As calls for improving the quality and cost efficiency of oncology increase, future empirical work is needed to examine the responsiveness of oncologists' treatment decision making to incentives among patients of all ages and insurance types.Keywords
This publication has 25 references indexed in Scilit:
- The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firmsJournal of Health Economics, 2011
- Targeted Therapy for Advanced Colorectal Cancer — More Is Not Always BetterNew England Journal of Medicine, 2009
- Limits on Medicare's Ability to Control Rising Spending on Cancer DrugsNew England Journal of Medicine, 2009
- Cost of Care for Elderly Cancer Patients in the United StatesJNCI: Journal of the National Cancer Institute, 2008
- Prescription Drug Spending Trends In The United States: Looking Beyond The Turning PointHealth Affairs, 2008
- Insurance Status and the Use of Guideline Therapy in the Treatment of Selected CancersJournal of Clinical Oncology, 2005
- Annual Report to the Nation on the Status of Cancer, 1975–2002, Featuring Population-Based Trends in Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2005
- Variability And Growth In Spending For Outpatient Specialty PharmaceuticalsHealth Affairs, 2005
- The Price Tag on Progress — Chemotherapy for Colorectal CancerNew England Journal of Medicine, 2004
- Pricing, Profits, and Technological Progress in the Pharmaceutical IndustryJournal of Economic Perspectives, 1993